480 related articles for article (PubMed ID: 31931541)
1. A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.
Michel M; Kalliga E; Labenz C; Straub BK; Wörns MA; Galle PR; Schattenberg JM
Z Gastroenterol; 2020 Jan; 58(1):57-62. PubMed ID: 31931541
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
4. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
Alexander M; Loomis AK; van der Lei J; Duarte-Salles T; Prieto-Alhambra D; Ansell D; Pasqua A; Lapi F; Rijnbeek P; Mosseveld M; Waterworth DM; Kendrick S; Sattar N; Alazawi W
BMC Med; 2019 May; 17(1):95. PubMed ID: 31104631
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
Oda K; Uto H; Mawatari S; Ido A
Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
[TBL] [Abstract][Full Text] [Related]
6. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
[TBL] [Abstract][Full Text] [Related]
7. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
Marengo A; Rosso C; Bugianesi E
Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
Argyrou C; Moris D; Vernadakis S
J BUON; 2017; 22(1):6-20. PubMed ID: 28365930
[TBL] [Abstract][Full Text] [Related]
9. Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.
Bril F; Cusi K
Diabetes Care; 2017 Mar; 40(3):419-430. PubMed ID: 28223446
[TBL] [Abstract][Full Text] [Related]
10. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC.
Kim H; Lee DS; An TH; Park HJ; Kim WK; Bae KH; Oh KJ
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925827
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma with silent and cirrhotic non-alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder.
Ikeda H; Suzuki M; Takahashi H; Kobayashi M; Okuse N; Moriya H; Koike J; Maeyama S; Yotsuyanagi H; Itoh F
Pathol Int; 2006 Jan; 56(1):40-5. PubMed ID: 16398679
[TBL] [Abstract][Full Text] [Related]
14. Minimally invasive percutaneous endovascular therapies in the management of complications of non-alcoholic fatty liver disease (NAFLD): A case report.
Salsamendi J; Pereira K; Kang K; Fan J
J Radiol Case Rep; 2015 Sep; 9(9):36-43. PubMed ID: 26629307
[TBL] [Abstract][Full Text] [Related]
15. [Research on the natural history of non-alcoholic fatty liver disease should be taken seriously].
Zhao ZH; Liu XL; Fan JG
Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):81-84. PubMed ID: 28297791
[TBL] [Abstract][Full Text] [Related]
16. Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma.
Weinmann A; Alt Y; Koch S; Nelles C; Düber C; Lang H; Otto G; Zimmermann T; Marquardt JU; Galle PR; Wörns MA; Schattenberg JM
BMC Cancer; 2015 Apr; 15():210. PubMed ID: 25884354
[TBL] [Abstract][Full Text] [Related]
17. Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma: A Growing Epidemic?
Yopp AC; Choti MA
Dig Dis; 2015 Sep; 33(5):642-7. PubMed ID: 26398208
[TBL] [Abstract][Full Text] [Related]
18. Transarterial Chemoembolization of Hepatocellular Carcinoma: Propensity Score Matching Study Comparing Survival and Complications in Patients with Nonalcoholic Steatohepatitis Versus Other Causes Cirrhosis.
Young S; Sanghvi T; Rubin N; Hall D; Roller L; Charaf Y; Golzarian J
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):65-75. PubMed ID: 31686136
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease.
Makri E; Goulas A; Polyzos SA
Arch Med Res; 2021 Jan; 52(1):25-37. PubMed ID: 33334622
[TBL] [Abstract][Full Text] [Related]
20. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
